Jim Simons Bei Gene, Ltd. Transaction History

Renaissance Technologies LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $1.66 Million - $2.48 Million	9,300 New	9,300 $1.66 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $303,140 - $465,152	2,300 New	2,300 $310,000
Q1 2020 May 14, 2020	SELL	$121.84 - $173.19 $3.73 Million - $5.3 Million	-30,619 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$115.78 - $208.34 $3.55 Million - $6.38 Million	30,619 New	30,619 $5.08 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.